250 related articles for article (PubMed ID: 8201224)
1. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.
Stiehl A; Walker S; Stiehl L; Rudolph G; Hofmann WJ; Theilmann L
J Hepatol; 1994 Jan; 20(1):57-64. PubMed ID: 8201224
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis with Ulcerative Colitis: A Pediatric Case.
Fujita Y; Sugaya T; Inui A; Yoshihara S
Tohoku J Exp Med; 2021 Feb; 253(2):109-112. PubMed ID: 33551380
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.
O'Brien CB; Senior JR; Arora-Mirchandani R; Batta AK; Salen G
Hepatology; 1991 Nov; 14(5):838-47. PubMed ID: 1937390
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis.
Komatsu K; Shimosegawa T; Kikuchi S; Uchi M; Maruhama Y; Kisara N; Ueno Y; Toyota T
Intern Med; 2000 Dec; 39(12):1049-53. PubMed ID: 11197788
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
8. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
9. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
10. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
11. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study.
Vleggaar FP; van Buuren HR; van Berge Henegouwen GP; Hop WC; van Erpecum KJ
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):171-5. PubMed ID: 11246617
[TBL] [Abstract][Full Text] [Related]
12. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
13. [Primary sclerosing cholangitis].
Stiehl A
Internist (Berl); 2004 Jan; 45(1):27-32. PubMed ID: 14735241
[TBL] [Abstract][Full Text] [Related]
14. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
Stiehl A
Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of primary sclerosing cholangitis with ursodeoxycholic acid].
Stiehl A; Raedsch R
Z Gastroenterol Verh; 1989 Jul; 24():136. PubMed ID: 2474928
[No Abstract] [Full Text] [Related]
17. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
18. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
Lindor KD
N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099
[TBL] [Abstract][Full Text] [Related]
19. Colitis-associated sclerosing cholangitis in children: a single centre experience.
Noble-Jamieson G; Heuschkel RB; Torrente F; Hadzic N; Zilbauer M
J Crohns Colitis; 2013 Nov; 7(10):e414-8. PubMed ID: 23485432
[TBL] [Abstract][Full Text] [Related]
20. Bile acids for primary sclerosing cholangitis.
Chen W; Gluud C
Cochrane Database Syst Rev; 2003; (2):CD003626. PubMed ID: 12804480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
